Grunenthal to commercialize Horizon Pharma's DUEXIS in Latin America

Horizon Pharma, Inc. (NASDAQ: HZNP) a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that it entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America. 

"As this is our first out-license of DUEXIS outside the United States, we are especially pleased to partner in Latin America with Grunenthal, a worldwide leader in the promotion of pain products," said Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma.  "This agreement, in addition to our recent U.S. co-promotion with Mallinckrodt, the pharmaceutical business of Covidien, is a continuation of our strategy to expand the availability of DUEXIS to patients worldwide."

"We are excited about the addition of DUEXIS to our existing product portfolio in Latin America," said Jose Maria Mora, acting executive vice president, Grunenthal Latin America.

Source:

Horizon Pharma, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Analysis of antibodies could be new tool for predicting prognosis and choosing therapy for RA patients